Molecular Biology Services for TME Research

In the field of cancer research, understanding the tumor microenvironment (TME) and its molecular mechanisms is essential for developing effective therapeutic strategies. Alfa Cytology offers exceptional molecular biology services for TME research.

Molecular Mechanisms in TME

Targeting specific molecules or pathways in the TME shows promise for developing novel therapeutic strategies against tumor growth, metastasis, and treatment resistance. Tumor cells evade immune surveillance within the TME by upregulating immune checkpoint molecules like PD-L1 and inducing chronic inflammation through NF-κB signaling and cytokines such as TNF-α and IL-6. They secrete immunosuppressive factors like TGF-β and IL-10 to suppress immune responses and promote immune escape. Tumors promote angiogenesis through HIF-1α and VEGF, leading to impaired drug delivery and immune cell infiltration. Molecular biology services offer valuable insights into gene expression patterns, protein profiles, genetic alterations, epigenetic modifications, and functional properties of key molecules within the TME. By employing techniques such as next-generation sequencing (NGS), single-cell sequencing, quantitative polymerase chain reaction (qPCR), and DNA methylation profiling, researchers can uncover key molecular mechanisms driving TME dysregulation.

Fig. 1 Crossroads between molecular patterns and tumor microenvironment. (Barthel L, et al, 2022)

Molecular Biology Services for TME Research

By characterizing the TME at the molecular level, researchers and clinicians can identify unique features that may influence tumor behavior and response to therapy. We offer customized molecular biology services to greatly enhance the depth and breadth of TME research, potentially leading to breakthroughs in cancer diagnosis, treatment, and even prevention. Our services include, but are not limited to:

• Analysis of Gene Mutations in TME
  We offer a comprehensive array of services aimed at identifying and characterizing the genetic alterations present within the TME, providing researchers with valuable insights into the mutational landscape of the TME.
• Analysis of Signaling Pathways and Molecular Targets in TME
  We provide clients with valuable insights into the signaling pathways and molecular targets in the TME, thereby facilitating their progress in cancer research and the development of enhanced treatment strategies.
• Molecular Characterization Services for Cancer Metastasis in TME
  We provide specialized molecular characterization services for cancer metastasis analysis in the TME, advancing diagnosis, prognosis, and targeted therapies.
• Analysis of Epigenetic Regulation in TME
  We are committed to analyzing the epigenetic alterations in different cell types within the TME, empowering clients to unravel the complexities of epigenetic regulation and its impact on tumor-immune interactions.
• Identification of Molecular Subtypes in TME
  We specialize in the identification of molecular subtypes in the TME, offering comprehensive services aimed at unraveling the complex interplay between tumor cells and the immune system.
• Prognostic Modeling Services for TME Research
  We employ innovative bioinformatics tools and approaches to develop prognostic models tailored to the unique TME of various cancer types.
• Analysis of Non-Coding RNA-Mediated Regulation in TME
  We offer a range of services to unravel the intricate regulatory networks mediated by non-coding RNA in the tumor microenvironment.

At Alfa Cytology, we excel in conducting comprehensive analysis to support researchers in gaining valuable insights into the genetic alterations, immune dysfunctions, signaling pathways, and epigenetic modifications that drive dysregulation in the TME. Contact us today to learn more about our services and how we can assist you in unraveling the complexities of the tumor microenvironment.

Reference

1. Barthel L, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev, 2022;41(1):53-75.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.